ROIV — Roivant Sciences Income Statement
0.000.00%
Last trade - 00:00- $9.05bn
- $3.32bn
- $61.28m
- 54
- 68
- 75
- 72
Annual income statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 67.7 | 23.8 | 55.3 | 61.3 |
| Cost of Revenue | ||||
| Gross Profit | 66.6 | 21.7 | 46.3 | 48.2 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 493 | 979 | 1,335 | 1,207 |
| Operating Profit | -425 | -956 | -1,280 | -1,146 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -561 | -899 | -924 | -1,225 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -568 | -900 | -924 | -1,230 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | 1,201 | -809 | -845 | -1,009 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 1,123 | -809 | -845 | -1,009 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.974 | -1.29 | -1.33 | -1.6 |
| Dividends per Share |